LakeShore Biopharma Co's total revenue is $320M, below the sector sector average of $1.4B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2024
Trailing 12 months ending Mar 2024
The latest total revenue for LSB is $320M as of March 2024. That compares with $54M in the prior-year period — up 489.2% year over year. That is below the sector sector average of $1.4B. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.
Over the past year, LSB's total revenue moved from $54M to $320M — a 489.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co's operating scale or balance-sheet position.
Against its sector companies, LSB currently prints $320M for total revenue, while the sector average sits near $1.4B. That is roughly 77.3% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.
A total revenue figure of $320M for LSB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.4B. Explore the charts below for those layers of context.
After noting LSB's total revenue ($320M), review year-over-year change from $54M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.